Tubocurarine (original) (raw)
Explore a selection of our essential drug information below, or:
Generic Name
Tubocurarine
DrugBank Accession Number
DB01199
Background
Tubocurarine is a non-depolarizing neuromuscular blocking agent and the first identified curare alkaloid.1 Curare is one of the names used to describe plant-derived poisons used by indigenous South Americans to coat the tips of hunting arrows and darts, which were typically derived from plants of the genera Chondrodendron and Strychnos.1 Tubocurarine is a benzylisoquinoline derivative and shares this structural backbone with a number of plant-derived alkaloids, including morphine and papaverine.2 It was first isolated by Harold King in 1935 and was used clinically to induce neuromuscular blockade during surgeries, particularly those involving the abdomen.4 Tubocurarine's clinical use was limited by its relatively long duration of action (30-60 minutes)4 and a number of significant side effects.6 Safer and more pharmacokinetically favorable non-depolarizing neuromuscular blockers, such as rocuronium, have largely replaced the use of tubocurarine in the clinical setting.6
Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 609.7312
Monoisotopic: 609.296462054
Chemical Formula
C37H41N2O6
Synonyms
- (+)-tubocurarine
- 7',12'-dihydroxy-6,6'-dimethoxy-2,2',2'-trimethyltubocuraranium
- d-tubocurarine
- Tubocurarin
- Tubocurarine
- Tubocurarinum
Indication
Not Available
Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
Pharmacodynamics
Not Available
Mechanism of action
Tubocurarine exerts its neuromuscular blocking effects via inhibition of acetylcholine (ACh) activity.1 It exerts a sort of reversible competitive antagonistic effect at post-synaptic nicotinic receptors, reducing the probability of activation via ACh by repeatedly associating and dissociating from these receptors - in doing so, tubocurarine prevents depolarization of the affected nerves. This mechanism distinguishes tubocurarine and similars from other neuromuscular blocking agents and is the reason they are referred to as "non-depolarizing neuromuscular blockers".1
Target | Actions | Organism |
---|---|---|
ANeuronal acetylcholine receptor subunit alpha-2 | antagonist | Humans |
A5-hydroxytryptamine receptor 3A | antagonist | Humans |
UAcetylcholinesterase | inhibitor | Humans |
UNeuronal acetylcholine receptor subunit alpha-7 | Not Available | Humans |
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
1-2 hours
Clearance
Not Available
Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
Toxicity
Not Available
Pathways
Not Available
Not Available
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug | Interaction |
---|---|
Integrate drug-drug interactions in your software | |
1,2-Benzodiazepine | The risk or severity of CNS depression can be increased when Tubocurarine is combined with 1,2-Benzodiazepine. |
Acebutolol | Tubocurarine may increase the bradycardic activities of Acebutolol. |
Acetazolamide | The risk or severity of CNS depression can be increased when Acetazolamide is combined with Tubocurarine. |
Acetophenazine | The risk or severity of CNS depression can be increased when Acetophenazine is combined with Tubocurarine. |
Acetylcholine | The risk or severity of adverse effects can be increased when Tubocurarine is combined with Acetylcholine. |
Food Interactions
Not Available
Drug product information from 10+ global regionsOur datasets provide approved product information including: dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Ingredient | UNII | CAS | InChI Key |
---|---|---|---|
Tubocurarine chloride pentahydrate | 900961Z8VR | 6989-98-6 | WMIZITXEJNQAQK-GGDSLZADSA-N |
International/Other Brands
Tubarine
Brand Name Prescription Products
ATC Codes
- M03AA — Curare alkaloids
- M03A — MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
- M03 — MUSCLE RELAXANTS
- M — MUSCULO-SKELETAL SYSTEM
Drug Categories
- Alkaloids
- Amines
- Anticholinergic Agents
- Benzylisoquinolines
- Central Nervous System Depressants
- Cholinergic Agents
- Cholinesterase Inhibitors
- Cholinesterase substrates
- Curare Alkaloids
- Ganglion Blockers
- Heterocyclic Compounds, Fused-Ring
- Isoquinolines
- Muscle Relaxants
- Muscle Relaxants, Peripherally Acting Agents
- Musculo-Skeletal System
- Neuromuscular Agents
- Neuromuscular Blocking Agents
- Neuromuscular-Blocking Agents (Nondepolarizing)
- Neurotoxic agents
- Neurotransmitter Agents
- Nicotinic Antagonists
- OCT1 substrates
- Onium Compounds
- Peripheral Nervous System Agents
- Quaternary Ammonium Compounds
- Tetrahydroisoquinolines
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
Kingdom
Super Class
Class
Sub Class
Direct Parent
Alternative Parents
Tetrahydroisoquinolines / Anisoles / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Tetraalkylammonium salts / Trialkylamines / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organic salts / Hydrocarbon derivatives / Organic cations show 3 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / Alkyl aryl ether / Amine / Anisole / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Diaryl ether / Hydrocarbon derivative / Organic cation / Organic nitrogen compound / Organic salt / Organoheterocyclic compound / Organonitrogen compound / Organopnictogen compound / Oxacycle / Quaternary ammonium salt / Tertiary aliphatic amine / Tertiary amine / Tetraalkylammonium salt / Tetrahydroisoquinoline show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzylisoquinoline alkaloid (CHEBI:9774) / Isoquinoline alkaloids (C07547)
Affected organisms
- Humans and other mammals
UNII
CAS number
57-95-4
InChI Key
JFJZZMVDLULRGK-URLMMPGGSA-O
InChI
InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1
IUPAC Name
(1S,16R)-9,21-dihydroxy-10,25-dimethoxy-15,15,30-trimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2^{3,6}.1^{8,12}.1^{18,22}.0^{27,31}.0^{16,34}]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24,26,31,35-dodecaen-15-ium
SMILES
[H][C@@]12CC3=CC=C(OC4=C5C(CC[N+](C)(C)[C@]5([H])CC5=CC(OC6=C(OC)C=C(CCN1C)C2=C6)=C(O)C=C5)=CC(OC)=C4O)C=C3
General References
- Bowman WC: Neuromuscular block. Br J Pharmacol. 2006 Jan;147 Suppl 1:S277-86. doi: 10.1038/sj.bjp.0706404. [Article]
- Singla D, Sharma A, Kaur J, Panwar B, Raghava GP: BIAdb: a curated database of benzylisoquinoline alkaloids. BMC Pharmacol. 2010 Mar 5;10:4. doi: 10.1186/1471-2210-10-4. [Article]
- Matteo RS, Lieberman IG, Salanitre E, McDaniel DD, Diaz J: Distribution, elimination, and action of d-tubocurarine in neonates, infants, children, and adults. Anesth Analg. 1984 Sep;63(9):799-804. [Article]
- Huang L, Sang CN, Desai MS: A Chronology for the Identification and Disclosure of Adverse Effects of Succinylcholine. J Anesth Hist. 2019 Jul;5(3):65-84. doi: 10.1016/j.janh.2018.07.003. Epub 2018 Jul 29. [Article]
- Ball C, Westhorpe R: Muscle relaxants--d-tubocurarine. Anaesth Intensive Care. 2005 Aug;33(4):431. doi: 10.1177/0310057X0503300401. [Article]
- Bevan DR: Newer neuromuscular blocking agents. Pharmacol Toxicol. 1994 Jan;74(1):3-9. doi: 10.1111/j.1600-0773.1994.tb01065.x. [Article]
External Links
Human Metabolome Database
KEGG Compound
PubChem Compound
PubChem Substance
ChemSpider
BindingDB
RxNav
ChEBI
ChEMBL
ZINC
Therapeutic Targets Database
PharmGKB
Wikipedia
MSDS
Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more.
Phase | Status | Purpose | Conditions | Count | Start Date | Why Stopped | 100+ additional columns |
---|---|---|---|---|---|---|---|
Unlock 175K+ rows when you subscribe.View sample data |
Unlock 75,000+ rows when you subscribe
Explore data packages curated & structured to speed up your pharmaceutical research
Manufacturers
Not Available
Packagers
- Hospira Inc.
Dosage Forms
Form | Route | Strength |
---|---|---|
Solution | Intravenous | 3 mg / mL |
Solution | Intramuscular; Intravenous | 3 mg / mL |
Prices
Unit description | Cost | Unit |
---|---|---|
Tubocurarine cl 3 mg/ml vial | 0.37USD | ml |
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available
State
Solid
Experimental Properties
Not Available
Predicted Properties
Property | Value | Source |
---|---|---|
Water Solubility | 0.000323 mg/mL | ALOGPS |
logP | 3.12 | ALOGPS |
logP | 3.23 | Chemaxon |
logS | -6.3 | ALOGPS |
pKa (Strongest Acidic) | 8.54 | Chemaxon |
pKa (Strongest Basic) | 7.98 | Chemaxon |
Physiological Charge | 2 | Chemaxon |
Hydrogen Acceptor Count | 5 | Chemaxon |
Hydrogen Donor Count | 2 | Chemaxon |
Polar Surface Area | 80.62 Å2 | Chemaxon |
Rotatable Bond Count | 2 | Chemaxon |
Refractivity | 187.06 m3·mol-1 | Chemaxon |
Polarizability | 67.43 Å3 | Chemaxon |
Number of Rings | 7 | Chemaxon |
Bioavailability | 1 | Chemaxon |
Rule of Five | No | Chemaxon |
Ghose Filter | No | Chemaxon |
Veber's Rule | No | Chemaxon |
MDDR-like Rule | No | Chemaxon |
Predicted ADMET Features
Property | Value | Probability |
---|---|---|
Human Intestinal Absorption | - | 0.9757 |
Blood Brain Barrier | + | 0.7287 |
Caco-2 permeable | + | 0.6869 |
P-glycoprotein substrate | Substrate | 0.8917 |
P-glycoprotein inhibitor I | Non-inhibitor | 0.8855 |
P-glycoprotein inhibitor II | Non-inhibitor | 0.8385 |
Renal organic cation transporter | Non-inhibitor | 0.6081 |
CYP450 2C9 substrate | Non-substrate | 0.8397 |
CYP450 2D6 substrate | Non-substrate | 0.6012 |
CYP450 3A4 substrate | Substrate | 0.6597 |
CYP450 1A2 substrate | Non-inhibitor | 0.9365 |
CYP450 2C9 inhibitor | Non-inhibitor | 0.948 |
CYP450 2D6 inhibitor | Non-inhibitor | 0.9231 |
CYP450 2C19 inhibitor | Non-inhibitor | 0.9136 |
CYP450 3A4 inhibitor | Non-inhibitor | 0.9284 |
CYP450 inhibitory promiscuity | Low CYP Inhibitory Promiscuity | 0.9794 |
Ames test | Non AMES toxic | 0.5666 |
Carcinogenicity | Non-carcinogens | 0.9195 |
Biodegradation | Not ready biodegradable | 0.9401 |
Rat acute toxicity | 2.6331 LD50, mol/kg | Not applicable |
hERG inhibition (predictor I) | Weak inhibitor | 0.8786 |
hERG inhibition (predictor II) | Non-inhibitor | 0.5444 |
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)
Mass Spec (NIST)
Not Available
Spectra
Chromatographic Properties
Collision Cross Sections (CCS)
Adduct | CCS Value (Å2) | Source type | Source |
---|---|---|---|
[M-H]- | 251.2456291 | predicted | DarkChem Lite v0.1.0 |
[M-H]- | 250.9698291 | predicted | DarkChem Lite v0.1.0 |
[M-H]- | 245.9191291 | predicted | DarkChem Lite v0.1.0 |
[M-H]- | 240.99449 | predicted | DeepCCS 1.0 (2019) |
[M+H]+ | 246.8450291 | predicted | DarkChem Lite v0.1.0 |
[M+H]+ | 251.3768291 | predicted | DarkChem Lite v0.1.0 |
[M+H]+ | 245.8143291 | predicted | DarkChem Lite v0.1.0 |
[M+H]+ | 242.81938 | predicted | DeepCCS 1.0 (2019) |
[M+Na]+ | 247.2929291 | predicted | DarkChem Lite v0.1.0 |
[M+Na]+ | 252.7068291 | predicted | DarkChem Lite v0.1.0 |
[M+Na]+ | 245.2690291 | predicted | DarkChem Lite v0.1.0 |
[M+Na]+ | 248.42522 | predicted | DeepCCS 1.0 (2019) |
Targets
Build, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock new insights and accelerate drug research.Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane
Specific Function
Acetylcholine receptor activity
Gene Name
CHRNA2
Uniprot ID
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Wenningmann I, Dilger JP: The kinetics of inhibition of nicotinic acetylcholine receptors by (+)-tubocurarine and pancuronium. Mol Pharmacol. 2001 Oct;60(4):790-6. [Article]
- Nishimura K, Kitamura Y, Taniguchi T, Agata K: Analysis of motor function modulated by cholinergic neurons in planarian Dugesia japonica. Neuroscience. 2010 Jun 16;168(1):18-30. doi: 10.1016/j.neuroscience.2010.03.038. Epub 2010 Mar 23. [Article]
- Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [Article]
- Liu M, Dilger JP: Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. doi: 10.1213/ane.0b013e31817b4469. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Forms serotonin (5-hydroxytryptamine/5-HT3)-activated cation-selective channel complexes, which when activated cause fast, depolarizing responses in neurons
Specific Function
Excitatory extracellular ligand-gated monoatomic ion channel activity
Gene Name
HTR3A
Uniprot ID
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
- Hefft S, Hulo S, Bertrand D, Muller D: Synaptic transmission at nicotinic acetylcholine receptors in rat hippocampal organotypic cultures and slices. J Physiol. 1999 Mar 15;515 ( Pt 3):769-76. [Article]
- Yan D, White MM: Interaction of d-tubocurarine analogs with mutant 5-HT(3) receptors. Neuropharmacology. 2002 Sep;43(3):367-73. [Article]
- Yan D, Meyer JK, White MM: Mapping residues in the ligand-binding domain of the 5-HT(3) receptor onto d-tubocurarine structure. Mol Pharmacol. 2006 Aug;70(2):571-8. Epub 2006 May 24. [Article]
- Peters JA, Malone HM, Lambert JJ: Antagonism of 5-HT3 receptor mediated currents in murine N1E-115 neuroblastoma cells by (+)-tubocurarine. Neurosci Lett. 1990 Mar 2;110(1-2):107-12. [Article]
- Emerit MB, Riad M, Fattaccini CM, Hamon M: Characteristics of [14C]guanidinium accumulation in NG 108-15 cells exposed to serotonin 5-HT3 receptor ligands and substance P. J Neurochem. 1993 Jun;60(6):2059-67. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Hydrolyzes rapidly the acetylcholine neurotransmitter released into the synaptic cleft allowing to terminate the signal transduction at the neuromuscular junction. Role in neuronal apoptosis
Specific Function
Acetylcholine binding
Gene Name
ACHE
Uniprot ID
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
- Radic Z, Taylor P: The influence of peripheral site ligands on the reaction of symmetric and chiral organophosphates with wildtype and mutant acetylcholinesterases. Chem Biol Interact. 1999 May 14;119-120:111-7. [Article]
- Golicnik M, Fournier D, Stojan J: Acceleration of Drosophila melanogaster acetylcholinesterase methanesulfonylation: peripheral ligand D-tubocurarine enhances the affinity for small methanesulfonylfluoride. Chem Biol Interact. 2002 Feb 20;139(2):145-57. [Article]
- Radic Z, Taylor P: Peripheral site ligands accelerate inhibition of acetylcholinesterase by neutral organophosphates. J Appl Toxicol. 2001 Dec;21 Suppl 1:S13-4. [Article]
- Gupta RC, Dettbarn WD: Potential of memantine, D-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents: soman, sarin, tabun and VX. Neurotoxicology. 1992 Fall;13(3):649-61. [Article]
- Bianchi DA, Hirschmann GS, Theoduloz C, Bracca AB, Kaufman TS: Synthesis of tricyclic analogs of stephaoxocanidine and their evaluation as acetylcholinesterase inhibitors. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2711-5. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin
Specific Function
Acetylcholine binding
Gene Name
CHRNA7
Uniprot ID
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
- Briggs CA, McKenna DG, Monteggia LM, Touma E, Roch JM, Arneric SP, Gopalakrishnan M, Sullivan JP: Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant. Eur J Pharmacol. 1999 Feb 5;366(2-3):301-8. [Article]
Enzymes
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters
Specific Function
Acetylcholinesterase activity
Gene Name
BCHE
Uniprot ID
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
- Aronson JK (2016). Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions (16th ed.). Amsterdam : Elsevier Science. [ISBN:9780444537164]
Transporters
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Electrogenic voltage-dependent transporter that mediates the transport of a variety of organic cations such as endogenous bioactive amines, cationic drugs and xenobiotics (PubMed:11388889, PubMed:11408531, PubMed:12439218, PubMed:12719534, PubMed:15389554, PubMed:16263091, PubMed:16272756, PubMed:16581093, PubMed:19536068, PubMed:21128598, PubMed:23680637, PubMed:24961373, PubMed:34040533, PubMed:9187257, PubMed:9260930, PubMed:9655880). Functions as a pH- and Na(+)-independent, bidirectional transporter (By similarity). Cation cellular uptake or release is driven by the electrochemical potential (i.e. membrane potential and concentration gradient) and substrate selectivity (By similarity). Hydrophobicity is a major requirement for recognition in polyvalent substrates and inhibitors (By similarity). Primarily expressed at the basolateral membrane of hepatocytes and proximal tubules and involved in the uptake and disposition of cationic compounds by hepatic and renal clearance from the blood flow (By similarity). Most likely functions as an uptake carrier in enterocytes contributing to the intestinal elimination of organic cations from the systemic circulation (PubMed:16263091). Transports endogenous monoamines such as N-1-methylnicotinamide (NMN), guanidine, histamine, neurotransmitters dopamine, serotonin and adrenaline (PubMed:12439218, PubMed:24961373, PubMed:35469921, PubMed:9260930). Also transports natural polyamines such as spermidine, agmatine and putrescine at low affinity, but relatively high turnover (PubMed:21128598). Involved in the hepatic uptake of vitamin B1/thiamine, hence regulating hepatic lipid and energy metabolism (PubMed:24961373). Mediates the bidirectional transport of acetylcholine (ACh) at the apical membrane of ciliated cell in airway epithelium, thereby playing a role in luminal release of ACh from bronchial epithelium (PubMed:15817714). Transports dopaminergic neuromodulators cyclo(his-pro) and salsolinol with lower efficency (PubMed:17460754). Also capable of transporting non-amine endogenous compounds such as prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) (PubMed:11907186). May contribute to the transport of cationic compounds in testes across the blood-testis-barrier (Probable). Also involved in the uptake of xenobiotics tributylmethylammonium (TBuMA), quinidine, N-methyl-quinine (NMQ), N-methyl-quinidine (NMQD) N-(4,4-azo-n-pentyl)-quinuclidine (APQ), azidoprocainamide methoiodide (AMP), N-(4,4-azo-n-pentyl)-21-deoxyajmalinium (APDA) and 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP) (PubMed:11408531, PubMed:15389554, PubMed:35469921, PubMed:9260930)
Specific Function
(r)-carnitine transmembrane transporter activity
Gene Name
SLC22A1
Uniprot ID
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
- Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, Koepsell H: Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem. 1996 Dec 20;271(51):32599-604. [Article]
- Lozano E, Herraez E, Briz O, Robledo VS, Hernandez-Iglesias J, Gonzalez-Hernandez A, Marin JJ: Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed Res Int. 2013;2013:692071. doi: 10.1155/2013/692071. Epub 2013 Jul 31. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Electrogenic voltage-dependent transporter that mediates the transport of a variety of organic cations such as endogenous bioactive amines, cationic drugs and xenobiotics (PubMed:9260930, PubMed:9687576). Functions as a Na(+)-independent, bidirectional uniporter (PubMed:21128598, PubMed:9687576). Cation cellular uptake or release is driven by the electrochemical potential, i.e. membrane potential and concentration gradient (PubMed:15212162, PubMed:9260930, PubMed:9687576). However, may also engage electroneutral cation exchange when saturating concentrations of cation substrates are reached (By similarity). Predominantly expressed at the basolateral membrane of hepatocytes and proximal tubules and involved in the uptake and disposition of cationic compounds by hepatic and renal clearance from the blood flow (PubMed:15783073). Implicated in monoamine neurotransmitters uptake such as histamine, dopamine, adrenaline/epinephrine, noradrenaline/norepinephrine, serotonin and tyramine, thereby supporting a physiological role in the central nervous system by regulating interstitial concentrations of neurotransmitters (PubMed:16581093, PubMed:17460754, PubMed:9687576). Also capable of transporting dopaminergic neuromodulators cyclo(his-pro), salsolinol and N-methyl-salsolinol, thereby involved in the maintenance of dopaminergic cell integrity in the central nervous system (PubMed:17460754). Mediates the bidirectional transport of acetylcholine (ACh) at the apical membrane of ciliated cell in airway epithelium, thereby playing a role in luminal release of ACh from bronchial epithelium (PubMed:15817714). Also transports guanidine and endogenous monoamines such as vitamin B1/thiamine, creatinine and N-1-methylnicotinamide (NMN) (PubMed:12089365, PubMed:15212162, PubMed:17072098, PubMed:24961373, PubMed:9260930). Mediates the uptake and efflux of quaternary ammonium compound choline (PubMed:9260930). Mediates the bidirectional transport of polyamine agmatine and the uptake of polyamines putrescine and spermidine (PubMed:12538837, PubMed:21128598). Able to transport non-amine endogenous compounds such as prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) (PubMed:11907186). Also involved in the uptake of xenobiotic 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP) (PubMed:12395288, PubMed:16394027). May contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable)
Specific Function
Acetylcholine transmembrane transporter activity
Gene Name
SLC22A2
Uniprot ID
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
- Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81. [Article]
Drug created at June 13, 2005 13:24 / Updated at August 02, 2024 07:33